FDA de­vel­op­ing guid­ance on re­al-world da­ta qual­i­ty is­sues, of­fi­cials say

As the FDA grap­ples with how to use re­al-world da­ta for reg­u­la­to­ry de­ci­sions, two FDA of­fi­cials wrote in a per­spec­tive pub­lished last Fri­day in the Clin­i­cal Jour­nal of the Amer­i­can So­ci­ety of Nephrol­o­gy that the agency is de­vel­op­ing guid­ance on da­ta qual­i­ty is­sues unique to the re­al-world da­ta set­ting and re­lat­ed study de­sign con­sid­er­a­tions.

Al­iza Thomp­son and Mary Ross South­worth of the Di­vi­sion of Car­dio­vas­cu­lar and Re­nal Prod­ucts with­in FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) ex­plain: “Al­though the FDA has ex­pe­ri­ence us­ing ob­ser­va­tion­al (non­in­ter­ven­tion­al) study de­signs in the post­mar­ket set­ting to eval­u­ate prod­uct risks in broad pop­u­la­tions, us­ing non­ran­dom­ized method­olo­gies to de­ter­mine ef­fec­tive­ness can be prob­lem­at­ic be­cause of con­cerns about the abil­i­ty to ad­e­quate­ly con­trol for con­found­ing, se­lec­tion bias, and the pos­si­bil­i­ty of mis­clas­si­fi­ca­tion er­ror.”

New da­ta stan­dards will need to be de­vel­oped and the FDA is “cur­rent­ly ex­plor­ing,” they write, when the use of ob­ser­va­tion­al da­ta “may be ap­pro­pri­ate for eval­u­at­ing ef­fec­tive­ness from a broad pol­i­cy per­spec­tive and al­so, as in­di­vid­ual drug man­u­fac­tur­ers sub­mit pro­pos­als for us­ing re­al world da­ta to sup­port mar­ket­ing ap­pli­ca­tions.”

The draft guid­ance in de­vel­op­ment is not on CDER’s 2019 guid­ance agen­da, but the FDA did pub­lish draft guid­ance in May on re­al-world ev­i­dence (RWE) sub­mis­sions. Last De­cem­ber, the agency al­so re­leased its frame­work for the use of RWE.

“There is wide­spread recog­ni­tion that there will be a learn­ing curve and that demon­stra­tion projects will play a crit­i­cal role in defin­ing how and when re­al world da­ta and re­al world ev­i­dence can be used,” Thomp­son and South­worth add.

Kid­ney Dis­ease

They al­so dis­cuss how re­al-world da­ta and RWE could pro­vide a way to ac­cel­er­ate the de­vel­op­ment of ther­a­pies that im­prove the lives of pa­tients with kid­ney dis­ease.

“Many have not­ed the po­ten­tial to in­te­grate RCTs [ran­dom­ized con­trolled tri­als] in­to the da­ta-rich clin­i­cal care set­ting of pa­tients on dial­y­sis, and ef­forts are un­der­way to un­der­stand and ad­dress cur­rent chal­lenges to do­ing so,” they ex­plain. “In RCTs of pa­tients with com­mon kid­ney dis­eases, such as di­a­bet­ic kid­ney dis­ease, re­al world da­ta could be used to fa­cil­i­tate the iden­ti­fi­ca­tion and en­roll­ment of pa­tients in­to tri­als. Study method­olo­gies aimed at cap­tur­ing key ef­fi­ca­cy out­comes us­ing both tra­di­tion­al meth­ods, and elec­tron­ic health records or claims da­ta could pro­vide in­sight in­to the chal­lenges and op­por­tu­ni­ties of us­ing re­al world da­ta to as­sess out­comes of in­ter­est by en­abling a com­par­i­son be­tween the two.”

But they warn that giv­en the “size of the pop­u­la­tion with stage 4 and 5 CKD [chron­ic kid­ney dis­ease] and frag­men­ta­tion of health care among var­i­ous US health care sys­tems, suc­cess­ful use of such da­ta will like­ly re­quire col­lab­o­ra­tion among re­searchers and the ag­gre­ga­tion of re­al world da­ta from mul­ti­ple sources. How­ev­er, these nov­el ap­proach­es should not sup­plant larg­er ef­forts to in­clude these pop­u­la­tions in reg­is­tra­tion tri­als for drugs, where ap­pro­pri­ate, or con­duct ded­i­cat­ed RCTs in these pop­u­la­tions.”


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta are com­ing fast

After coming under heavy fire from consumer groups ready to pummel them for grabbing the FDA’s orphan status for remdesivir — reserved to encourage the development of rare disease therapies — Gilead CEO Daniel O’Day had some explaining to do about the company’s approach to providing access to this drug to patients suffering from Covid-19. And he set aside time over the weekend to patiently explain how they are making their potential pandemic drug available in a new program — one he feels can better be used to address a growing pack of infected patients desperately seeking remdesivir under compassionate use provisions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

The average level of investment required for a biotech start-up to succeed is increasing every year, elevating the pressure even further on venture capital to make smart financial investments. Financial investment alone, however, does not always guarantee that exciting innovations can be transformed into real businesses that make a meaningful difference to patients.

Beyond just capital

At Astellas Venture Management (AVM) – a wholly-owned venture capital organization within Astellas, headquartered in the San Francisco Bay Area – capital is just one of the ingredients we offer to add value to our biotechnology investments and partnerships. We generally take a strategic investor approach for companies in our invested portfolio, providing access to expertise, technology and/or resources in addition to the injection of finance. An equity investment from AVM can include access to Astellas’ research and development (R&D) capabilities and expertise, and a global network of partner academic institutions and biotechnology companies, to help advance and accelerate the start-up’s innovation.

Covid-19 roundup: In­ter­cept, blue­bird and a grow­ing list of biotechs feel the pain as pan­dem­ic man­gles FDA, R&D sched­ules

Around 100 staffers at Boston area hospitals have now tested positive for Covid-19, spotlighting the growing risk that the pandemic will sideline many of the most essential workers in healthcare as caseloads peak in the US and around the globe. With more than 3,400 deaths, Spain has become the latest country to surpass the official death count attributed to the new coronavirus in China, where the outbreak originated. As of Thursday morning, confirmed global cases had crossed 470,000 and the death count eclipsed 21,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

Two days after Gilead won orphan drug status for remdesivir as a potential treatment for Covid-19, they’re handing it back.

The company was slammed from several sides after Gilead reported that the FDA had come through with the special status, which comes with 7 years of market exclusivity, the waiver of FDA fees and some tax credits as well. Typically, everyone who can get orphan status lands it without much of a fuss, but Democratic presidential candidate Bernie Sanders, Public Citizen and other consumer groups were outraged.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

NIAID director Anthony Fauci has left no doubts that it takes 12 to 18 months to get a new vaccine tested and in commercial use, in the best of circumstances. But in times of a global emergency — like these — maybe there’s another, faster route to follow.

In an SEC filing on Tuesday, Moderna $MRNA staked out a record-setting pathway to getting their mRNA vaccine into the frontline of the healthcare response as early as this fall. The SEC filing notes that CEO Stéphane Bancel told Goldman Sachs that an emergency use approval could allow the vaccine to go to healthcare workers and certain individuals in a matter of months — presumably provided the NIH sees the safety and efficacy data they would need from the Phase I.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.

The pharma giant reported Monday morning that it has decided to hit the brakes on most new study starts and pause enrollment for most ongoing studies. Lilly adds that it is continuing dosing for ongoing studies, “but with study-by-study consideration.”

The pandemic has severely disrupted healthcare systems around the globe, says Lilly, making it difficult or impossible to conduct studies at many research sites. And there’s no timeline for when it expects to get back on track.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

You can add Pfizer, Merck and — as we found out Friday morning — Vertex to the growing list of pharma giants hitting the pause button on a range of clinical trials. But not everyone in R&D is getting a red light.

Vertex says that it’s doing its best to keep working its pipeline strategy, coming up with a plan “to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Bris­tol My­ers sus­pends clin­i­cal tri­als, grounds field team; Vir ush­ers an­ti­body can­di­dates to hu­man test­ing

The global nature of the Covid-19 pandemic is manifesting more profoundly every day. With Spain’s death toll now surpassing China’s and India on full lockdown, the number of confirmed cases around the world has exceeded 436,000 while recoveries edged close to 112,000.

While the outbreak derails R&D at another pharma giant, several drugmakers have some encouraging updates on both experimental and repurposed molecules. Philanthropic campaigns in anticipation of the economic fallout continue. An Australian biotech is taking extreme measures to hunker down. There’s also an alternative epidemiology model emerging out of the UK, stirring up more discussion regarding the true extent of the infections in the country.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

Stock buybacks are not to be permitted for companies that will be bailed out in the coronavirus stimulus package, Congressional leaders have signaled. To what degree the biopharma industry has relied on buybacks for earnings growth in recent years, and if the trend continues, are the big questions as scrutiny into the practice heightens and balance sheets weaken with the coronavirus pandemic wreaking havoc on global economies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.